Efficacy and safety of inclisiran, evolocumab and alirocumab in patients with high, very high and extreme cardiovascular risk

Aim. To compare efficacy and safety of inclisiran, evolocumab and alirocumab in patients with high, very high and extreme cardiovascular risk (according to data from the Federal Research Center for Cardiology and Microbiology, Novosibirsk).Material and methods. This prospective two-year observationa...

全面介紹

書目詳細資料

發表在:	Российский кардиологический журнал
Main Authors:	N. G. Lozhkina, N. P. Dobrovolskaya, S. N. Artemenko, M. V. Shipunov, A. D. Sharonin, V. A. Koltyugina, V. S. Timofeev, M. I. Voyevoda
格式:	Article
語言:	俄语
出版:	«FIRMA «SILICEA» LLC 2025-04-01
主題:	lipid-lowering therapy high, very high and extreme cardiovascular risk
在線閱讀:	https://russjcardiol.elpub.ru/jour/article/view/5869